Marianne holds a bachelor’s degree in pharmacology and a post graduate diploma in microbiology and immunology. She moved from industrial pharmacy to market research in 2012 and found her passion in oncology. The rapidly evolving oncology landscape fascinates her, fulfils her thirst for knowledge and it fills her with hope to see better outcomes offered to patients every day. Marianne specialises in solid tumours and has also worked across multiple haematological malignancies. ASCO and ESMO weeks are her best weeks of the year.

Having joined HRW in 2009, and leveraging a degree in history that leaned heavily into story driven communication, a career in market research seemed like the perfect fit for Kirsty. With the launch of OR:BIT in 2016, she was enthusiastic to join the team and take the opportunity to develop an academic interest in the complex and evolving science of the Oncology space. Kirsty’s particular passion lies in patient research, and having the opportunity to get close to a multitude of different patients, to learn about their experiences and hear first-hand about their challenges and hopes surrounding living with, or dying from, cancer is inspirational. Her core areas of specialism include NSCLC, myeloma, head and neck, prostate and haematological malignancies such as AML, CML and CLL.

Dana entered market research with a background in Decision Sciences and Healthcare Policy and Management, and has spent her 5 years in the industry dedicated to HRW’s OR:BIT team. She has supported oncology brands in both HCP and Patient market understanding, across all stages of brand life cycle, and across both solid tumors (including lung, breast, colorectal, prostate and ovarian cancers, among others), as well as hematological malignancies (including AML, CML, MCL, and MM, among others). She directs her passion for oncology to drug development - attending conferences to learn about and support market research teams in bringing novel treatment platforms to market to transform treatment for cancer patients (including, CAR-T, cell and gene therapies, and radioligand therapies).

Sophie developed her interest in oncology during her MSci in biochemistry, in particular studying cancer immunotherapies. She joined HRW in 2016, pursuing her interest in oncology and discovering a passion for patient research. Sophie has expertise across multiple solid tumour and haematological cancers, ranging from the most common types to rare cancers, and is always looking for new opportunities to connect with cancer patients.

Dylan holds an educational background in neuroscience and moved into market research in 2017 upon realizing that the industry was ideal for those who wanted to continuously learn new topics whilst having an impact on the broader healthcare industry. Dylan’s expertise in oncology relates specifically to the interplay among biomarker expression, therapeutic efficacy, and patient selection through companion and / or complementary diagnostics. This interest spans numerous indications and tumor types, including both solid and liquid malignancies.

Victoria started in pharmaceutical market research in 2013, initially focusing on chronic conditions and mental health. Her experience in oncology developed over time starting in 2017 and has grown to include research in solid tumor types (e.g., prostate and breast cancer) and hematological malignancies (acute myeloid leukemia, multiple myeloma). She has a keen interest in listening to patient stories and exploring opportunities to make their experience better. She is currently pursuing her Master’s in Public Health, concentrating on Health Policy and Management.

Liz came into market research with a background in strategic communication and a graduate degree in Advertising, where her research focused on activating health behavior changes in underserved populations. She been involved in oncology market research for the past decade, supporting brand development at various stages of their life cycle from foundational journey and launch, through expanding indications & portfolio strategy, all the way through patent extension. A seasoned moderator, Liz has led & conducted thousands of interviews with patients, caregivers, physicians, nurses, and other key stakeholders. She has wide-ranging experience with immune-oncology agents & targeted therapies across a range of solid tumors, in both metastatic and adjuvant settings. In particular, Liz has enjoyed her work in breast cancer, urothelial carcinoma, and developing pan-tumor strategy.

With a background in psychology and business, Alex loves putting her curiosity to work exploring human behavior to build strong brands. She fell in love with the pharma industry from the start but knew she was home when she did her first oncology project over a decade ago. Since then, she’s focused heavily on Oncology, specializing in solid tumors with a particular interest in targeted therapies and rare malignancies. Alex loves exploring the complex realities of those living with and treating cancer in order to help her clients empathize and navigate this space as they bring live changing solutions to market.